Another group of patients that may benefit from such an undertaking are those with tumours displaying passenger mutations of ENO1. 35ENO1 and ENO2 are genes encoding the glycolytic enzyme enolase, which converts 2-phosphoglyceric acid into phosphoenolpyruvate. Here, ENO2 is linked to neoplasm.